FUSEN PHARM (01652) releases interim financial results, with a shareholder's net loss of 23.136 million yuan, narrowing by 37.37% year-on-year.
Fosun Pharma (01652) announced its interim results for the six months ending June 30, 2025, with a profit of 1.11...
FUSEN PHARM(01652) released its interim results for the six months ending on June 30, 2025, with a revenue of 111 million yuan (RMB), a decrease of 43.31% compared to the same period last year. Shareholders' net loss was 23.136 million yuan, a decrease of 37.37% compared to the same period last year. Basic loss per share was 3 cents.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
